29 September 2011 Business
Industry news, October 2011
AstraZeneca launched the Nexium brand for prescription use in 2000. The company has started filing marketing applications for an OTC version – the EU application landed in June and the US equivalent is planned for the first half of 2013.
Under the terms, Pfizer will pay $250 million up front and commit to making undisclosed further payments based on product launches and sales if they happen. For this, it will get exclusive rights to the OTC version. If all goes to plan, Pfizer will launch the product in the US in 2014.
The two companies are investigating similar deals in relation to other brands in the AstraZeneca portfolio from which OTC products might be derived. Notably, Pfizer has been given first refusal on Rhinocort Aqua (glucocorticosteroid budesonide) anti-inflammatory pump sprays for the treatment of non-infectious rhinitis, such as hay fever and house dust mite allergy.
17 June 2013 Research
Cheap nickel catalysis offers alternative to expensive enzymatic resolution
17 June 2013 News and Analysis
Thinktank says hundreds of millions of pounds of tax breaks are going to city business firms and would be better spent elsewh...
14 June 2013 Research
Chemical mapping could help unpick the biology of extinct animals